MedTrace Logo

Immunogenicity of Influenza Vaccine in Long Term Care

NCT02933723 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2021-03-09

No results posted yet for this study

Summary

The study is designed to evaluated if adjuvanted vaccine elicits higher T cell and B cell responses than non-adjuvanted standard dose influenza vaccine in nursing home residents.

Conditions

Interventions

PROCEDURE

Blood Draw

Sampling 3 blood draws Day 0 for humoral and CMI 30 ml prior to vaccination (up to 2 week prior to vaccination) Day 7 for CMI 20 ml (+/- 1 day) Day 28 for humoral 10 ml (+/- 3 days)

Sponsors & Collaborators

  • Case Western Reserve University

    collaborator OTHER

  • University Hospitals Cleveland Medical Center

    collaborator OTHER

  • Seqirus

    collaborator INDUSTRY

  • Insight Therapeutics, LLC

    lead OTHER

Principal Investigators

  • H. Edward Davidson, PharmD · Insight Therapeutics, LLC

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2017-05-24
Completion
2021-09-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02933723 on ClinicalTrials.gov